Natco Pharma announced its Q2 FY26 results, showcasing a total revenue of INR 14,630 Mn. Pharma export formulations contributed INR 11,470 Mn, while domestic formulations reached INR 1,054 Mn. The company reported an EBITDA of INR 6,792 Mn with a margin of 46.4%. Net profit after tax stood at INR 5,179 Mn, translating to earnings per share of INR 28.94.
Financial Performance Overview
Natco Pharma reported strong financial results for Q2 FY26. Key highlights include:
- Total Revenue: INR 14,630 Mn
- Pharma Export Formulations: INR 11,470 Mn
- Domestic Formulations Revenue: INR 1,054 Mn
- EBITDA: INR 6,792 Mn
- EBITDA Margin: 46.4%
- Profit After Tax (PAT): INR 5,179 Mn
- Earnings Per Share: INR 28.94
Revenue Breakdown by Segment
The revenue for Q2 FY26 can be further broken down as follows:
- API Revenue: INR 539 Mn
- Formulation Exports: INR 11,470 Mn
- Domestic Formulation: INR 1,054 Mn
- Crop Health Sciences: INR 524 Mn
- Other Operating & Non-Operating Income: INR 1,043 Mn
This resulted in a Consolidated Total Revenue of INR 14,630 Mn.
Profit & Loss Highlights
Key figures from the Profit & Loss Statement include:
- Total Expenses: INR 7,838 Mn
- Finance Cost: INR 131 Mn
- Depreciation: INR 524 Mn
- Profit Before Tax (PBT): INR 6,137 Mn
- Tax: INR 958 Mn
This yielded a PAT Margin of 35.4%.
Product Pipeline Update – USA
Natco Pharma has a robust product pipeline in the USA, which includes:
- 30 Para IVs in the pipeline, with over 20 FTFs (including Sole and Shared)
- 13 Approved products (either tentative or fully)
Strategic Investments
Natco Pharma is actively investing in innovative therapies, including:
- eGenesis: Focused on xenotransplantation.
- NRC – 2694: An orally administered small-molecule tyrosine kinase inhibitor.
- Cellogen Therapeutics: Focused on advanced cellular engineering.
- Eyestem: Developing a treatment for dry Age-Related Macular Degeneration (AMD).
- Stero Therapeutics: Developing novel therapy for metabolic diseases.
Earnings Call Details
An earnings call to discuss the operational and financial performance will be held on November 14th, 2025, at 4 PM IST. Dial-in numbers are available for India, US, UK, and Singapore.
Source: BSE